☰

Drug Discovery_

A HUMAN-FIRST

APPROACH

We enable better drug discovery by probing the vastness of chemical space hidden within the human microbiome, leveraging immense AI-powered computational genetics and chemistry engines to illuminate new frontiers for new medicines.

Our Approach

The Future
is inside us

The human-first approach yields novel structure scaffolds/ motifs harnessed from rich bioactive natural products facilitate the discovery of new molecules with high biological relevance, and tractable to clinical data.

Big Data

Diverse and Ever-growing

We leverage clinical cohort data to identify disease-targeting small molecules generated by the human microbiome. Our approach is to build upon a comprehensive and ever-expanding database, encompassing diverse clinical metadata, meta genomes,

and biomarkers with worldwide coverage, linked to virtual chemical space. This robust database solidifies the data-centric foundation of our research. Powered by a globally deployable analytics platform, we utilise cloud computing to generate insights from big data.

Superior, Rapid, Cost-effective

The MAIDEN™ Platform

Our Maiden™ platform increases the chances of discovering new therapeutics and enable the probing of new and traditionally undruggable targets.

1
2
3

FIND

BIND

VALIDATE

Microbial functional genome mining and computational chemistry reveals actionable chemical spaces related to disease status and pathophysiology

Candidate small molecules and molecular targets are assessed in silico

Virtual small molecule leads coupled to clinical data are validated against human targets

Remarkable Therapeutics_

GENOMES

To

CHEMICAL SPACE

To

NEW THERAPEUTICS

Human Validation Upfront

Human evidence-guided small molecule discovery ensures bio-relevance from the outset. Extensive datasets yield patient population responses. Notably, traceability of the data back to clinical source throughout our process underscores its value.

Biocompatibility

The small molecules drug candidates, derived from humans, off inherent validation of their efficacy and the potential for favorable safety profiles from the outset.

Broad Therapeutic Potential

The microbiome plays a crucial role in numerous health and disease conditions, presenting ample opportunities to identify drugs for a wide range of ailments.

Drugging the Undruggable with a High Success Rate

Our approach significantly enhances the likelihood of discovering new therapeutics and successfully targeting traditionally challenging or “undruggable” molecular targets.

Human Validation Upfront

Human evidence-guided small molecule discovery ensures bio-relevance from the outset. Extensive datasets yield patient population responses. Notably, traceability of the data back to clinical source throughout our process underscores its value.

Biocompatibility

The small molecules drug candidates, derived from humans, off inherent validation of their efficacy and the potential for favorable safety profiles from the outset.

Broad Therapeutic Potential

The microbiome plays a crucial role in numerous health and disease conditions, presenting ample opportunities to identify drugs for a wide range of ailments.

Drugging the Undruggable with a High Success Rate

Our approach significantly enhances the likelihood of discovering new therapeutics and successfully targeting traditionally challenging or “undruggable” molecular targets.

Get in Touch

If you have a general question for us or want to explore a partnership opportunity, then please reach out to us here…

[ Contact Us + ]